Although, further studies will exploit the safety profile of RS5517 in vivo, understanding that β-catenin signaling negatively regulates NHERF1 in CRC tumorigenesis will trigger the refinement of Wnt-targeted approaches to overcome the therapeutic resistance occurring at early disease stages. The gene discussed is NHERF1; the disease is colorectal carcinoma.